Bioaffinity Technologies, Stock Performance
| BIAF Stock | USD 0.38 0.05 15.15% |
The firm shows a Beta (market volatility) of 1.47, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, BioAffinity Technologies, will likely underperform. At this point, bioAffinity Technologies, has a negative expected return of -1.41%. Please make sure to confirm BioAffinity Technologies,'s total risk alpha, skewness, rate of daily change, as well as the relationship between the maximum drawdown and accumulation distribution , to decide if bioAffinity Technologies, performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days bioAffinity Technologies, has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
1 | Veterans Research Foundation Spotlights CyPath Lungs Addition to the Federal Supply Schedule | 12/05/2024 |
2 | Insider Trading | 12/06/2024 |
3 | bioAffinity Technologies Set for Continued Expansion in 2025 | 12/12/2024 |
4 | Acquisition by Zannes Timothy P of 8641 shares of BioAffinity Technologies, subject to Rule 16b-3 | 01/10/2025 |
5 | bioAffinity Technologies CEO receives salary increase | 01/14/2025 |
6 | bioAffinity Secures Australian Patent for Revolutionary Lung Cancer Detection Test - StockTitan | 01/22/2025 |
7 | Acquisition by Joyce Roby of 11867 shares of BioAffinity Technologies, at 1.58 subject to Rule 16b-3 | 02/21/2025 |
8 | How Will bioAffinitys 1.4M Capital Raise Impact Existing Shareholders - StockTitan | 02/26/2025 |
| Begin Period Cash Flow | 11.4 M | |
| Free Cash Flow | -6.1 M |
BioAffinity |
BioAffinity Technologies, Relative Risk vs. Return Landscape
If you would invest 104.00 in bioAffinity Technologies, on December 6, 2024 and sell it today you would lose (66.00) from holding bioAffinity Technologies, or give up 63.46% of portfolio value over 90 days. bioAffinity Technologies, is currently does not generate positive expected returns and assumes 7.4491% risk (volatility on return distribution) over the 90 days horizon. In different words, 66% of stocks are less volatile than BioAffinity, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BioAffinity Technologies, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioAffinity Technologies,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as bioAffinity Technologies,, and traders can use it to determine the average amount a BioAffinity Technologies,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1896
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BIAF |
Estimated Market Risk
| 7.45 actual daily | 66 66% of assets are less volatile |
Expected Return
| -1.41 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.19 actual daily | 0 Most of other assets perform better |
Based on monthly moving average BioAffinity Technologies, is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioAffinity Technologies, by adding BioAffinity Technologies, to a well-diversified portfolio.
BioAffinity Technologies, Fundamentals Growth
BioAffinity Stock prices reflect investors' perceptions of the future prospects and financial health of BioAffinity Technologies,, and BioAffinity Technologies, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioAffinity Stock performance.
| Return On Equity | -1.52 | ||||
| Return On Asset | -0.7 | ||||
| Profit Margin | (1.19) % | ||||
| Operating Margin | (0.87) % | ||||
| Current Valuation | 6.11 M | ||||
| Shares Outstanding | 15.48 M | ||||
| Price To Book | 1.65 X | ||||
| Price To Sales | 0.64 X | ||||
| Revenue | 2.53 M | ||||
| EBITDA | (7.63 M) | ||||
| Net Income | (7.94 M) | ||||
| Cash And Equivalents | 214.4 K | ||||
| Cash Per Share | 0.08 X | ||||
| Total Debt | 1.58 M | ||||
| Current Ratio | 0.02 X | ||||
| Book Value Per Share | 0.30 X | ||||
| Cash Flow From Operations | (6.04 M) | ||||
| Earnings Per Share | (0.91) X | ||||
| Market Capitalization | 19.81 M | ||||
| Total Asset | 8.22 M | ||||
| Retained Earnings | (44.6 M) | ||||
| Working Capital | 1.72 M | ||||
About BioAffinity Technologies, Performance
By analyzing BioAffinity Technologies,'s fundamental ratios, stakeholders can gain valuable insights into BioAffinity Technologies,'s financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BioAffinity Technologies, has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioAffinity Technologies, has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 4.46 | 4.23 | |
| Return On Tangible Assets | (1.19) | (1.25) | |
| Return On Capital Employed | (1.53) | (1.46) | |
| Return On Assets | (0.87) | (0.91) | |
| Return On Equity | (1.88) | (1.79) |
Things to note about bioAffinity Technologies, performance evaluation
Checking the ongoing alerts about BioAffinity Technologies, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for bioAffinity Technologies, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioAffinity Technologies, generated a negative expected return over the last 90 days | |
| BioAffinity Technologies, has high historical volatility and very poor performance | |
| BioAffinity Technologies, has some characteristics of a very speculative penny stock | |
| BioAffinity Technologies, has a very high chance of going through financial distress in the upcoming years | |
| bioAffinity Technologies, currently holds 1.58 M in liabilities. bioAffinity Technologies, has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about BioAffinity Technologies,'s use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 2.53 M. Net Loss for the year was (7.94 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| bioAffinity Technologies, currently holds about 214.4 K in cash with (6.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08. | |
| Roughly 30.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: How Will bioAffinitys 1.4M Capital Raise Impact Existing Shareholders - StockTitan |
- Analyzing BioAffinity Technologies,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioAffinity Technologies,'s stock is overvalued or undervalued compared to its peers.
- Examining BioAffinity Technologies,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioAffinity Technologies,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioAffinity Technologies,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioAffinity Technologies,'s stock. These opinions can provide insight into BioAffinity Technologies,'s potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for BioAffinity Stock analysis
When running BioAffinity Technologies,'s price analysis, check to measure BioAffinity Technologies,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies, is operating at the current time. Most of BioAffinity Technologies,'s value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies,'s price. Additionally, you may evaluate how the addition of BioAffinity Technologies, to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |